Completed PHASE1 INTERVENTIONAL 2-arm NCT03350373

Clinical Pharmacology of FYU-981 (Final Formulation)

Clinical Pharmacology Study of Final Formulation of FYU-981 Administered to Healthy Male Adults

Sponsor: Fuji Yakuhin Co., Ltd.

Conditions Healthy

Interventions FYU-981

Updated 5 times since 2017 Last updated: Dec 11, 2017 Started: Nov 6, 2017 Primary completion: Nov 29, 2017 Completion: Nov 29, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Healthy and is currently completed. Fuji Yakuhin Co., Ltd. leads this study, which shows 5 recorded versions since 2017 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Dec 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Nov 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fuji Yakuhin Co., Ltd.
Mochida Pharmaceutical Company, Ltd.

Data source: Mochida Pharmaceutical Company, Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hachiōji, Japan